Treatment with a growth factor-protein mixture inhibits formation of mineralized nodules in osteogenic cell cultures grown on titanium.
Despite wide clinical application, the efficacy of platelet-rich plasma (PRP) for repairing bone defects and enhancing osseointegration of metal implants is still subject of debate. This study aimed to evaluate the effects of a well-defined PRP-like mixture containing platelet-derived growth factor-BB, transforming growth factor (TGF)-beta1, TGF-beta2, albumin, fibronectin, and thrombospondin [growth factors (GFs) + proteins] on the development of the osteogenic phenotype on titanium (Ti) in vitro. Human alveolar bone-derived osteoblastic cells were subcultured on Ti discs and exposed during the first 7 days to osteogenic medium supplemented with GFs + proteins and to osteogenic medium alone thereafter up to 14 days. Control cultures were exposed to only osteogenic medium. Dose-response experiments were carried out using rat primary calvarial cells exposed to GFs + proteins and 1:10 or 1:100 dilutions of the mixture. Treated human-derived cell cultures exhibited a significantly higher number of cycling cells at days 1 and 4 and of total cells at days 4 and 7, significantly reduced alkaline phosphatase (ALP) activity at days 4, 7, and 10, and no Alizarin red-stained areas (calcium deposits) at day 14, indicating an impairment in osteoblast differentiation. Although the 1:10 and 1:100 dilutions of the mixture restored the proliferative activity of rat-derived osteogenic cells to control levels and promoted a significant increase in ALP activity at day 10 compared with GFs + proteins, mineralized nodule formation was only observed with the 1:100 dilution ( approximately 50% of the control). These results showed that a PRP-like protein mixture inhibits development of the osteogenic phenotype in both human and rat osteoblastic cell cultures grown on Ti.
de Oliva
Marcos Andrade
MA
Cell Culture Laboratory, School of Dentistry of Ribeirão Preto, Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (PC), Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.
Maximiano
William Marcatti Amarú
WM
de Castro
Larissa Moreira Spínola
LM
da Silva
Paulo Eliandro
PE
Fernandes
Roger Rodrigo
RR
Ciancaglini
Pietro
P
Beloti
Márcio Mateus
MM
Nanci
Antonio
A
Rosa
Adalberto Luiz
AL
de Oliveira
Paulo Tambasco
PT
D000818:Animals; D001842:Bone and Bones / Q000166:cytology; D002113:Calcification, Physiologic; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005353:Fibronectins / Q000494:pharmacology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008855:Microscopy, Electron, Scanning; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D053657:Platelet-Rich Plasma; D051381:Rats; D012709:Serum Albumin / Q000494:pharmacology*; D019699:Thrombospondins / Q000494:pharmacology*; D013997:Time Factors; D023822:Tissue Engineering; D014025:Titanium; D053773:Transforming Growth Factor beta1 / Q000494:pharmacology; D053781:Transforming Growth Factor beta2 / Q000494:pharmacology
D005353:Fibronectins; D036341:Intercellular Signaling Peptides and Proteins; D010982:Platelet-Derived Growth Factor; D012709:Serum Albumin; D019699:Thrombospondins; D053773:Transforming Growth Factor beta1; D053781:Transforming Growth Factor beta2; D014025:Titanium